PCN30 THE COSTS OF TREATING PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL CANCER (NSCLC) WITH BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE COMPARED WITH PEMETREXED PLUS CISPLATIN IN INDUCTION AND MAINTENANCE THERAPY IN GERMANY AND ITALY
May 1, 2009, 00:00
10.1016/S1098-3015(10)73267-8
https://www.valueinhealthjournal.com/article/S1098-3015(10)73267-8/fulltext
Title :
PCN30 THE COSTS OF TREATING PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL CANCER (NSCLC) WITH BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE COMPARED WITH PEMETREXED PLUS CISPLATIN IN INDUCTION AND MAINTENANCE THERAPY IN GERMANY AND ITALY
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)73267-8&doi=10.1016/S1098-3015(10)73267-8
First page :
Section Title :
Open access? :
No
Section Order :
692